Maha E Houssen1, Rasha H El-Mahdy2, Dina A Shahin3. 1. Biochemistry Department, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt. 2. Medical Microbiology and Immunology Department, Faculty of Medicine, Mansoura University, Mansoura, Dakahlia, Egypt. 3. Internal Medicine Department, Rheumatology and Immunology Unit, Faculty of Medicine, Mansoura University, Mansoura, Dakahlia, Egypt.
Abstract
AIM: To assess the serum levels of soluble toll-like receptor (sTLR2) as an endogenous negative regulator of TLR2 signaling in systemic lupus erythematosus (SLE) patients, to investigate the correlation between sTLR2 and SLE disease activity index (SELDAI), SLE-related cardiovascular risk factors and ventricular dysfunction and to evaluate the effect of different therapeutic regimens on serum sTLR2 levels. METHODS: Ninety-six SLE patients, along with 30 healthy controls, were enrolled in the study. Echocardiography measurements were performed. Serum levels of (sTLR2) were measured using enzyme-linked immunosorbent assay (ELISA). Serum lipid profiles, uric acid and creatinine were also detected. RESULTS: Mean serum levels of sTLR2 in SLE patients was 3.98 ± 4.4 ng/mL, which was significantly decreased as compared with that of the control group (11.3 ± 4.9 ng/mL; P < 0.0001). sTLR2 was negatively correlated with SELDAI, low-density lipoprotein (LDL) and left ventricular diastolic dysfunction. sTLR2 levels were increased in patients receiving hydroxychloroquine, statins and corticosteroids. CONCLUSION: Serum sTLR2 can attenuate disease activity and negatively impact left ventricular diastolic dysfunction and hypercholersterelemia in SLE patients. Statins, corticosteroids and chloroquine increase sTLR2 levels.
AIM: To assess the serum levels of soluble toll-like receptor (sTLR2) as an endogenous negative regulator of TLR2 signaling in systemic lupus erythematosus (SLE) patients, to investigate the correlation between sTLR2 and SLE disease activity index (SELDAI), SLE-related cardiovascular risk factors and ventricular dysfunction and to evaluate the effect of different therapeutic regimens on serum sTLR2 levels. METHODS: Ninety-six SLEpatients, along with 30 healthy controls, were enrolled in the study. Echocardiography measurements were performed. Serum levels of (sTLR2) were measured using enzyme-linked immunosorbent assay (ELISA). Serum lipid profiles, uric acid and creatinine were also detected. RESULTS: Mean serum levels of sTLR2 in SLEpatients was 3.98 ± 4.4 ng/mL, which was significantly decreased as compared with that of the control group (11.3 ± 4.9 ng/mL; P < 0.0001). sTLR2 was negatively correlated with SELDAI, low-density lipoprotein (LDL) and left ventricular diastolic dysfunction. sTLR2 levels were increased in patients receiving hydroxychloroquine, statins and corticosteroids. CONCLUSION: Serum sTLR2 can attenuate disease activity and negatively impact left ventricular diastolic dysfunction and hypercholersterelemia in SLEpatients. Statins, corticosteroids and chloroquine increase sTLR2 levels.
Authors: Consuelo P C Marques; Vandilson P Rodrigues; Larissa C de Carvalho; Louise P Nichilatti; Mayra M Franco; Fernando José B Patrício; Marcelo Magalhães; Marcelo S de Andrade; Bruno B Benatti Journal: Clin Rheumatol Date: 2021-02-11 Impact factor: 2.980
Authors: Bethany M Henrick; Xiao-Dan Yao; Ameer Y Taha; J Bruce German; Kenneth Lee Rosenthal Journal: Front Immunol Date: 2016-08-02 Impact factor: 7.561
Authors: Md Jakir Hossain; Elena Morandi; Radu Tanasescu; Nanci Frakich; Marzia Caldano; David Onion; Tola A Faraj; Clett Erridge; Bruno Gran Journal: Front Immunol Date: 2018-03-14 Impact factor: 7.561
Authors: Bartosz Sokół; Norbert Wąsik; Roman Jankowski; Marcin Hołysz; Barbara Więckowska; Paweł Jagodziński Journal: PLoS One Date: 2016-05-25 Impact factor: 3.240